Posted by Michael Wonder on 05 Apr 2022
Consultation now open - review of base case discount rate at 3A.1 of the PBAC Guidelines
5 April 2022 - The Commonwealth has entered into a new Strategic Agreement in relation to reimbursement, health technology assessment and other matters with Medicines Australia acting on behalf of the innovator medicines industry.
The Agreement includes a commitment that the Minister for Health seeks the advice of the PBAC as to whether the base case discount rate at 3A.1 of the PBAC Guidelines aligns with international best practice.
